Tag: dvt
Ensuring the right treatment for patients with PE and DVT
In this short video, Michael Kostrzewa (Baden, Switzerland) and Rashid Akhtar (London, UK) discuss the latest approaches to the treatment of acute pulmonary embolism...
Mitchell Silver joins Contego Medical as chief medical officer
Contego Medical recently announced that Mitchell Silver, an interventional cardiologist and vascular medicine specialist, has joined the team as chief medical officer (CMO).
A press...
Using “wall-to-wall” mechanical thrombectomy in DVT treatment
Experience wall-to-wall thrombectomy in action with Manuela Konert from Leipzig, Germany! In this brief video, Konert walks through a deep vein thrombosis (DVT) case...
Why treat DVT interventionally with a “wall-to-wall” mechanical thrombectomy approach?
In a recent interview, Marie Josee van Rijn from Rotterdam, the Netherlands and Emma Wilton from Oxford, UK, provided insight into the transformative power...
Six-month outcomes from phase-one trial of anti-inflammatory drug to assess benefit...
The open-label phase of the DEXTERITY-AFP trial investigating the Bullfrog microinfusion device—which involves the perivenous injection of the anti-inflammatory drug dexamethasone to improve patency...
One-year CLOUT data demonstrate low rate of PTS following treatment with...
David Dexter (Sentara Vascular Specialists, Norfolk, USA) shared one-year data from the CLOUT registry this week at The VEINS 2023 (28–30 October, Las Vegas,...
The pulmonary arterial tree—it is time we branch out
Nicolas J Mouawad (McLaren Health System, Bay City, USA) urges vascular surgeons to “get out of their comfort zone” and become more involved in...
ClotTriever “makes fast, safe and efficient thrombectomy possible”
This advertorial is sponsored by Inari Medical
“We need to eliminate symptoms as fast as possible—it is not OK just to make things a little...
JETi registry provides “remarkable results” for peripheral thrombectomy system
Presenting “remarkable results” from the JETi registry—a prospective, multicenter, observational study which collected real-world data on the safety, performance and clinical benefits of the...
Mechanical thrombectomy: ClotTriever offers “extended window” for DVT treatment
This advertorial, sponsored by Inari Medical, is only available in selected countries and geographies.
During a recent webinar hosted by Inari Medical, a multidisciplinary group...
Vascular News 98 – June 2023 US Edition
In this issue:
Extensive coverage of CX 2023, including a full report of the BASIL-2 randomised controlled trial results
New guidelines: Chris Twine (Bristol, UK)...
Vascular News 98 – June 2023
In this issue:
Extensive coverage of CX 2023, including a full report of the BASIL-2 randomised controlled trial results
New guidelines: Chris Twine (Bristol,...
CX 2023 seeks consensus in “rapidly” progressing venous field
The CX 2023 Venous & Lymphatic programme is set to be a “highlight” of this year’s meeting, CX co-chair and executive board member Erin...
New study demonstrates IVC filters “safe and effective” in treating venous...
Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into...
New mechanical thrombectomy systems unlock possibilities for the treatment of venous...
Gerd Grözinger (Tübingen, Germany) chats with Bernhard Gebauer (Berlin, Germany) at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14...
Arteriovenous graft use linked to venous thromboembolism risk in haemodialysis patients
In an observational cohort study of Medicare beneficiaries receiving haemodialysis, the use of an arteriovenous graft (AVG) compared with an arteriovenous fistula (AVF) was...
ClotTriever deemed a “game-changer” in deep vein thrombosis treatment
This advertorial, sponsored by Inari Medical, is only available in selected countries and geographies.
“I am finally very confident I have a device that...
Why ClotTriever is a “gamechanger” for the treatment of deep vein...
Andrew Wigham (Oxford, UK) and Rick De Graaf (Friedrichshafen, Germany) discuss the current state of deep vein thrombosis (DVT) treatment at the Leipzig Interventional...
New retrospective data demonstrate midline catheters composed of advanced biomaterials may...
Access Vascular has shared initial findings from a retrospective review of patient records that demonstrate an increase in dwell times compared to other commercially...
Cordis makes strategic investment in E2, a developer of next-generation thrombectomy...
Cordis has announced a strategic investment venture that will expand the scope of the global cardiovascular technology company into the venous thromboembolism (VTE) market...
Cardiovascular Systems partners with Innova Vascular to develop full line of...
Cardiovascular Systems Inc (CSI) recently announced it has partnered with Innova Vascular (Innova) to develop a full line of novel thrombectomy devices.
According to a...
Thrombus dissolution with EKOS™ Acoustic Pulse Thrombolysis™ in everyday clinical practice
At the EKOS symposium at LINC 2019, Nils Kucher (Zurich, Switzerland), Houman Jalaie (Aachen, Germany) and Mert Dumantepe (Istanbul, Turkey) share their experiences in...
Clearing the clot: New horizons in deep vein thrombosis treatment
In this supplement: --Life post-ATTRACT: The new challenge of DVT treatment --The future of DVT intervention in Europe: what needs to happen next --"With...
ATTRACT fails to meet primary endpoint, but experts agree results are...
Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of...
Advances and challenges in the treatment of deep vein thrombosis
The goal of management of venous thromboembolic disease is to prevent thrombus extension or embolisation and to prevent early and late episodes of recurrence....
Two new real-world studies confirm positive efficacy and safety profile of...
Janssen Pharmaceuticals and its development partner, Bayer, announced on 23 October 2016 results of two new real-world studies confirming the positive benefit-risk profile of...
